Male Reproductive Cancers

mTOR Inhibitor Blocks Prostate Cancer Metastasis in Preclinical Model

Investigators have characterized how pro-invasion messenger RNAs direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling — and then developed a clinically relevant ATP site inhibitor of mTOR, INK128, “which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure,” they noted in Nature, published online February 22.

Next post in Prostate Cancer